References
- Delioukina M, Zain J, Palmer JM, et al. Reduced-intensity allogeneic hematopoietic cell transplantation using fludarabine-melphalan conditioning for treatment of mature T-cell lymphomas. Bone Marrow Transplant 2012;47:65–72.
- Reddy P, Maeda Y, Horary K, et al. Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. Proc Natl Acad Sci USA 2004;101:3921–3926.
- Weisenburger DD, Savage KJ, Harris NL, et al. Peripheral T-cell lymphoma, not otherwise specified; a report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood 2011;117:3402–3408
- Reimer P, Rudiger T, Geissinger E, et al. Autologous stem cell transplantation as first line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol 2009;27:106–113
- Le Gouill S, Milpied N, Buzyn A, et al. Graft versus lymphoma effect for aggressive T-cell lymphomas in adults:a study by the Societe Francaise de greffe de Moelle et de Therapie Cellulaire. J Clin Oncol 2008;26:2264–2271.
- Corradini P, Dodero A, Zallio F, et al. Graft versus lymphoma effect in relapsed peripheral T cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoetic cells. J Clin Oncol 2004;22:2172–2176.
- Colbert N, Andrieu JM, Bernard J. Pulse methylprednisolone therapy in angioimmunoblastic lymphadenopathy. Acta Haematol 1982;68:307–308
- Sackstein R, Borenstein M. The effects of corticosteroids on lymphocyte recirculation in humans: analysis of the mechanism of impaired lymphocyte migration to lymph node following methylprednisolone administration. J Investig Med 1995;43:68–77.
- Piekarz RL, Frye R, Turner M, et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 2009; 27:5410–5417.
- Li JY, Horwitz S, Moskowitz A, et al. Management of cutaneous T cell lymphoma: new and emerging targets and treatment options. Cancer Manag Res 2012;4:75–89.
- Leng C, Gries M, Ziegler J, et al. Reduction of graft-versus- host disease by histone deacetylase inhibitor suberonylanilide hydroxamic acid is associated with modulation of inflammatory cytokine milieu and involves inhibition of STAT1. Exp Hematol 2006; 34:776–787.
- Reddy P, Sun Y, Toubai T, et al. Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice. J Clin Invest 2008;118:2562–2573.
- Lucas JL, Mirshahpanah P, Haas-Stapleton E, et al. Induction of Foxp3 + regulatory T cells with histone deacetylase inhibitors. Cell Immunol 2009;257:97–104.
- Al-Yacoub N, Fecker LF, Möbs M, et al. Apoptosis induction by SAHA in cutaneous T-cell lymphoma cells is related to down regulation of c-FLIP and enhanced TRAIL signaling. J Invest Dermatol 2012;132:2263–74.
- Schmudde M, Friebe E, Sonnemann J, et al. Histone deacetylase inhibitors prevent activation of tumor-reactive NK cells and T cells but do not interfere with their cytolytic effector functions. Cancer Lett 2010;28;295:173–181.